Breaking News

Charles River Launches AAV and LVV Reference Materials Portfolio

Is designed to streamline Cell and Gene Therapy research and development as it scales to Good Manufacturing Practice quality.

Author Image

By: Charlie Sternberg

Associate Editor

Charles River Laboratories International, Inc. has launched its reference materials for its adeno associated virus (AAV) and lentiviral vector (LVV) portfolio, which is designed to streamline Cell and Gene Therapy (CGT) research and development as it scales to Good Manufacturing Practice- (GMP) quality.   “The launch of Charles River’s AAV and LVV reference materials portfolio is the latest in a series of enhancements in our CDMO products and services offerings,” says Ramin Baghirzade, PhD, Se...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters